Edgemont Capital Serves as Exclusive Financial Advisor to Siren Interactive in Recently Announced Sale of Company to Dohmen Life Science Services

NEW YORK & CHICAGO--()--Edgemont Capital Partners, LP, a leading independent investment banking firm providing merger and acquisition advisory services to healthcare companies, acted as exclusive financial advisor to Siren Interactive (“Siren”) in the recently announced sale of the company to Dohmen Life Science Services (“DLSS”), a subsidiary of the Dohmen Company, Edgemont said today. The transaction was originally announced on January 6.

Siren is a leading rare disease interactive relationship marketing company with expertise in addressing the challenges and unmet needs of patients, caregivers, and physicians dealing with the over 7,000 rare diseases affecting over 300 million people worldwide. Edgemont Capital Partners acted as the exclusive financial advisor to Siren in the transaction, which closed on December 31, 2014. David Blume, Managing Director and head of the firm’s Pharmaceutical Services Group, and Luke Mitchell, Managing Director led Edgemont’s transaction team.

“The needs of rare disease patients, their caregivers and physicians, are underserved. Despite greater awareness of the large number of rare diseases and those living with these conditions, access to information, including available therapies, care management, as well as patient and caregiver support through patient communities and effective ongoing communication remains a large unmet need. The development and introduction of pharmaceuticals to treat rare diseases is accelerating rapidly, increasing demand for services that optimally support access to and proper use of these therapies as part of the patient’s overall care,” said Blume.

Siren Interactive serves rare disease pharmaceutical and biotech companies by connecting patients with their brands. Siren is a pioneer in patient-driven decision making in commercialization of orphan drugs. Wendy White, president of Siren, founded the company as a result of her own personal struggle with a family member’s rare disease experience. Following the transaction, White joined DLSS as Senior Vice President of Dohmen’s Rare Disease segment.

“We retained Edgemont to advise us based on their proven track record and expertise in pharmaceutical services and M&A execution. They demonstrated a commitment to our transaction and provided exceptional advice. As the founder and CEO of a premium services company I appreciate when a professional services organization goes the extra mile as Edgemont did for us,” White commented.

About Dohmen Life Science Services
Intelligent outsourcing for the life sciences.™
Dohmen Life Science Services provides outsourced insight and infrastructure to entrepreneurs seeking speed, scale and certainty as they bring their biopharma or medical device products to market. Our industry experts help hundreds of companies preserve capital, mitigate risk and stay focused on the future by supplying the very best people, processes and tools within the areas of finance, technology, quality, regulatory compliance, supply chain, customer services and patient support. Dohmen Life Science Services is a subsidiary of the Dohmen Company. Privately held and headquartered in Milwaukee, Wisconsin, Dohmen has been finding ways to create a more efficient, effective and accessible healthcare supply system since 1858. More information can be found at DLSS.com and Dohmen.com.

About Siren
Siren Interactive is a rare disease marketing agency with unmatched expertise in addressing the challenges and unmet needs of patients, caregivers, and physicians dealing with the over 7,000 rare diseases affecting over 300 million people worldwide. For more than 15 years, across more than 30 different disease states, the Company has had a singular focus: Finding rare disease patients and connecting them to its clients’ brands. As trailblazers in recognizing that patient-driven decision making is central to successful orphan drug commercialization, Siren constantly innovates to meet patients and caregivers where they live. To learn more about Siren’s proprietary approaches to building trust relationships with rare disease stakeholders visit sireninteractive.com. Siren Interactive is a subsidiary of Dohmen Life Science Services. More information can be found at DLSS.com.

About Edgemont Capital Partners
Edgemont Capital Partners, LP (www.edgemontcapital.com), is an independent investment banking firm founded in 2001 providing merger and acquisition and financing advisory services to healthcare companies worldwide. The firm’s deep healthcare industry knowledge and extensive transaction expertise allows Edgemont to address healthcare companies' strategic (M&A) and financing needs with great success. The firm’s principals have closed over 100 transactions, representing more than $30 billion in value.

For more information on Edgemont Capital Partners’ expertise in pharmaceutical services or other healthcare sectors contact David Blume at +1 (212) 867-8937 and visit www.edgemontcapital.com.

Investment banking services are provided by Edgemont Capital Partners, L.P., a registered broker-dealer and member of FINRA and SIPC.

Contacts

MacMillan Communications
Mike MacMillan/Chris Sullivan
212.473.4442
chris@macmillancom.com

Contacts

MacMillan Communications
Mike MacMillan/Chris Sullivan
212.473.4442
chris@macmillancom.com